118 related articles for article (PubMed ID: 30187443)
1. The Influence of Diabetes Mellitus on Glucuronidation and Sulphation of Paracetamol in Patients with Febrile Neutropenia.
Stachowiak A; Szałek E; Karbownik A; Łojko A; Porażka J; Przewoźna I; Grabowski T; Wolc A; Grześkowiak E
Eur J Drug Metab Pharmacokinet; 2019 Apr; 44(2):289-294. PubMed ID: 30187443
[TBL] [Abstract][Full Text] [Related]
2. The concomitant use of lapatinib and paracetamol - the risk of interaction.
Karbownik A; Szałek E; Sobańska K; Grabowski T; Klupczynska A; Plewa S; Wolc A; Magiera M; Porażka J; Kokot ZJ; Grześkowiak E
Invest New Drugs; 2018 Oct; 36(5):819-827. PubMed ID: 29464465
[TBL] [Abstract][Full Text] [Related]
3. THE EFFECT OF TOTAL AND PARTIAL NEPHRECTOMY ON THE PHARMACOKINETICS OF INTRAVENOUS PARACETAMOL IN HUMANS.
Karbownik A; Polom W; Porazka J; Szalek E; Grabowski T; Wolc A; Matuszewski Marcin ; Grzesowiak E
Acta Pol Pharm; 2017 May; 74(3):929-935. PubMed ID: 29513963
[TBL] [Abstract][Full Text] [Related]
4. The comparative pharmacokinetics of modified-release and immediate-release paracetamol in a simulated overdose model.
Chiew A; Day P; Salonikas C; Naidoo D; Graudins A; Thomas R
Emerg Med Australas; 2010 Dec; 22(6):548-55. PubMed ID: 21143403
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of paracetamol in patients with chronic pancreatitis.
Siepsiak M; Szałek E; Karbownik A; Grabowski T; Mziray M; Adrych K; Grześkowiak E
Pharmacol Rep; 2016 Aug; 68(4):733-6. PubMed ID: 27127912
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of intravenous paracetamol in elderly patients.
Liukas A; Kuusniemi K; Aantaa R; Virolainen P; Niemi M; Neuvonen PJ; Olkkola KT
Clin Pharmacokinet; 2011 Feb; 50(2):121-9. PubMed ID: 21241071
[TBL] [Abstract][Full Text] [Related]
7. Glucuronidation and sulphation of paracetamol in HIV-positive patients and patients with AIDS.
O'Neil WM; Pezzullo JC; Di Girolamo A; Tsoukas CM; Wainer IW
Br J Clin Pharmacol; 1999 Dec; 48(6):811-8. PubMed ID: 10594484
[TBL] [Abstract][Full Text] [Related]
8. Influence of the Time of Intravenous Administration of Paracetamol on its Pharmacokinetics and Ocular Disposition in Rabbits.
Karbownik A; Bienert A; Płotek W; Grabowski T; Cerbin-Koczorowska M; Wolc A; Grześkowiak E
Eur J Drug Metab Pharmacokinet; 2017 Jun; 42(3):489-498. PubMed ID: 27485347
[TBL] [Abstract][Full Text] [Related]
9. Selection of 12-Hour Sustained-Release Acetaminophen (Paracetamol) Formulation Through Comparison of Pharmacokinetic Profiles of 4 Sustained-Release Prototype Formulations and Standard Acetaminophen Formulation: An Open-Label, Randomized, Proof-of-Principle Pharmacokinetic Study.
Yue Y; Liu DJ
Clin Pharmacol Drug Dev; 2018 Jan; 7(1):87-94. PubMed ID: 28816033
[TBL] [Abstract][Full Text] [Related]
10. Exposure to acetaminophen and all its metabolites upon 10, 15, and 20 mg/kg intravenous acetaminophen in very-preterm infants.
Flint RB; Roofthooft DW; van Rongen A; van Lingen RA; van den Anker JN; van Dijk M; Allegaert K; Tibboel D; Knibbe CAJ; Simons SHP
Pediatr Res; 2017 Oct; 82(4):678-684. PubMed ID: 28553988
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic drug-drug interaction between erlotinib and paracetamol: A potential risk for clinical practice.
Karbownik A; Szałek E; Sobańska K; Grabowski T; Wolc A; Grześkowiak E
Eur J Pharm Sci; 2017 May; 102():55-62. PubMed ID: 28232141
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and ocular disposition of paracetamol and paracetamol glucuronide in rabbits with diabetes mellitus induced by alloxan.
Bienert A; Kamińska A; Olszewski J; Gracz J; Grabowski T; Wolc A; Grześkowiak E
Pharmacol Rep; 2012; 64(2):421-7. PubMed ID: 22661194
[TBL] [Abstract][Full Text] [Related]
13. Acetaminophen protein adduct formation following low-dose acetaminophen exposure: comparison of immediate-release vs extended-release formulations.
James LP; Chiew A; Abdel-Rahman SM; Letzig L; Graudins A; Day P; Roberts D
Eur J Clin Pharmacol; 2013 Apr; 69(4):851-7. PubMed ID: 23052410
[TBL] [Abstract][Full Text] [Related]
14. Quantitative analysis of acetaminophen and its primary metabolites in small plasma volumes by liquid chromatography-tandem mass spectrometry.
Gicquel T; Aubert J; Lepage S; Fromenty B; Morel I
J Anal Toxicol; 2013 Mar; 37(2):110-6. PubMed ID: 23316031
[TBL] [Abstract][Full Text] [Related]
15. Comparative pharmacokinetics of Panadol Extend and immediate-release paracetamol in a simulated overdose model.
Tan C; Graudins A
Emerg Med Australas; 2006 Aug; 18(4):398-403. PubMed ID: 16842311
[TBL] [Abstract][Full Text] [Related]
16. Integrated pharmacokinetic-pharmacodynamic model for acetaminophen, ibuprofen, and placebo antipyresis in children.
Brown RD; Kearns GL; Wilson JT
J Pharmacokinet Biopharm; 1998 Oct; 26(5):559-79. PubMed ID: 10205771
[TBL] [Abstract][Full Text] [Related]
17. The pharmacokinetic profile of intravenous paracetamol in adult patients undergoing major abdominal surgery.
Owens KH; Medlicott NJ; Zacharias M; Curran N; Chary S; Thompson-Fawcett M; Reith DM
Ther Drug Monit; 2012 Dec; 34(6):713-21. PubMed ID: 23149443
[TBL] [Abstract][Full Text] [Related]
18. Plasma paracetamol concentrations and pharmacokinetics following rectal administration in neonates and young infants.
Hansen TG; O'Brien K; Morton NS; Rasmussen SN
Acta Anaesthesiol Scand; 1999 Sep; 43(8):855-9. PubMed ID: 10492416
[TBL] [Abstract][Full Text] [Related]
19. Single-dose pharmacokinetics of 2 or 3 tablets of biphasic immediate-release/extended-release hydrocodone bitartrate/acetaminophen (MNK-155) under fed and fasted conditions: two randomized open-label trials.
Devarakonda K; Kostenbader K; Giuliani MJ; Young JL
BMC Pharmacol Toxicol; 2015 Nov; 16():31. PubMed ID: 26614499
[TBL] [Abstract][Full Text] [Related]
20. Paracetamol (acetaminophen) protein adduct concentrations during therapeutic dosing.
Heard K; Green JL; Anderson V; Bucher-Bartelson B; Dart RC
Br J Clin Pharmacol; 2016 Mar; 81(3):562-8. PubMed ID: 26584404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
